BioAtla (BCAB)
(Real Time Quote from BATS)
$0.37 USD
+0.02 (5.71%)
Updated Aug 6, 2025 03:48 PM ET
After-Market: $0.37 0.00 (0.00%) 4:12 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCAB 0.37 +0.02(5.71%)
Will BCAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCAB
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know
BCAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCAB
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM ...
BioAtla presents data from ongoing dose escalation fo BA3182
BioAtla Approves 2025 Corporate Bonus Plan
12 Health Care Stocks Moving In Monday's After-Market Session